<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Article Tag Suite 1.1//EN"
  "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         article-type="research-article"
         xml:lang="en">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>American Journal of PharmTech Research</journal-title>
        <abbrev-journal-title abbrev-type="publisher">AJPTR</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="epub">2249-3387</issn>
      <publisher>
        <publisher-name>undefined</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AJPTR44068</article-id>
      <title-group>
        <article-title>Amlodipine Besylate, Croscarmellose sodium, &amp;#61538;-Cyclodextrin, sublingual</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>K</surname>
            <given-names>Vankani Ankit</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" iso-8601-date="2014-08-01">
        <month>08</month>
        <day>01</day>
        <year>2014</year>
      </pub-date>
      <volume>4</volume>
      <issue>4</issue>
      <abstract>
        <p>Amlodipine Besylate is a molecule used in Hypertension and currently available in tablet dosage form. The objective of present study was to develop and evaluate Amlodipine Besylate intraoral sublingual formulation for faster release and absorption. Four formulations containing varying concentrations of Croscarmellose sodium and b-Cyclodextrin were formulated. Various evaluations like weight variation, % friability, Hardness, diameter, water absorption ratio, wetting time, disintegration time, drug content and calibration curve were performed. From the results, it was concluded that all batches pass the evaluation tests with F4 showing the fastest wetting and Disintegration. From the data of Dissolution studies it was concluded that formulation F4 showed highest drug release in 10 minutes. It can be concluded that sublingual tablets of Amlodipine Besylate will prove to be patient friendly.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Formulation and Evaluation of Sublingual Tablets of Amlodipine Besylate Containing Beta-Cyclodextrin</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <!-- Full article body not available in metadata-only JATS export. See PDF/HTML galley. -->
  </body>
  <back/>
</article>
